Bedaquiline-Pretomanid-Linezolid (BPaL) Regimen
Treatment for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: Bedaquiline 400mg daily for 2 weeks, then 200mg 3x/week for 22 weeks; Pretomanid 200mg daily; Linezolid 600mg daily (often reduced to 300mg daily)
Effectiveness
90%
Safety Score
55%
Clinical Trials
8
Participants
650
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Bedaquiline 400mg daily for 2 weeks, then 200mg 3x/week for 22 weeks; Pretomanid 200mg daily; Linezolid 600mg daily (often reduced to 300mg daily)
Time to Effect
2-4 weeks for initial response, 2-3 months for culture conversion
Treatment Duration
6 months
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$3,000
Side Effect Mgmt:$2,000
Total Annual:$20,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$75,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$21,739
Cost per Remission
$22,727
Comparison vs Conventional longer MDR-TB regimen
Cost Difference
$-5,000/year
Less expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Bedaquiline-Pretomanid-Linezolid (BPaL) Regimen Outcomes
for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov